文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

揭示与奥拉帕利耐药和卵巢癌细胞 PEO1-OR 再敏化相关的 miRNA-mRNA 调控网络，该通路抑制剂为 ATR/CHK1 通路抑制剂。

Uncovering miRNA-mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of Ovarian Cancer PEO1-OR Cells with the ATR/CHK1 Pathway Inhibitors.

机构信息

Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.

Doctoral School of Exact and Natural Sciences, University of Lodz, Jana Matejki 21/23, 90-237 Lodz, Poland.

出版信息

Cells. 2024 May 17;13(10):867. doi: 10.3390/cells13100867.

DOI:10.3390/cells13100867
PMID:38786089
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11119970/
Abstract

Resistance to olaparib is the major obstacle in targeted therapy for ovarian cancer (OC) with poly(ADP-ribose) polymerase inhibitors (PARPis), prompting studies on novel combination therapies to enhance olaparib efficacy. Despite identifying various mechanisms, understanding how OC cells acquire PARPi resistance remains incomplete. This study investigated microRNA (miRNA) expression in olaparib-sensitive (PEO1, PEO4) and previously established olaparib-resistant OC cell lines (PEO1-OR) using high-throughput RT-qPCR and bioinformatic analyses. The role of miRNAs was explored regarding acquired resistance and resensitization with the ATR/CHK1 pathway inhibitors. Differentially expressed miRNAs were used to construct miRNA-mRNA regulatory networks and perform functional enrichment analyses for target genes with miRNet 2.0. TCGA-OV dataset was analyzed to explore the prognostic value of selected miRNAs and target genes in clinical samples. We identified potential processes associated with olaparib resistance, including cell proliferation, migration, cell cycle, and growth factor signaling. Resensitized PEO1-OR cells were enriched in growth factor signaling via PDGF, EGFR, FGFR1, VEGFR2, and TGFβR, regulation of the cell cycle via the G2/M checkpoint, and caspase-mediated apoptosis. Antibody microarray analysis confirmed dysregulated growth factor expression. The addition of the ATR/CHK1 pathway inhibitors to olaparib downregulated FGF4, FGF6, NT-4, PLGF, and TGFβ1 exclusively in PEO1-OR cells. Survival and differential expression analyses for serous OC patients revealed prognostic miRNAs likely associated with olaparib resistance (miR-99b-5p, miR-424-3p, and miR-505-5p) and resensitization to olaparib (miR-324-5p and miR-424-3p). Essential miRNA-mRNA interactions were reconstructed based on prognostic miRNAs and target genes. In conclusion, our data highlight distinct miRNA profiles in olaparib-sensitive and olaparib-resistant cells, offering molecular insights into overcoming resistance with the ATR/CHK1 inhibitors in OC. Moreover, some miRNAs might serve as potential predictive signature molecules of resistance and therapeutic response.

摘要

对聚（ADP-核糖）聚合酶抑制剂（PARPi）的卵巢癌（OC）的靶向治疗的主要障碍是耐药性，这促使人们研究新的联合治疗方法以增强奥拉帕利的疗效。尽管已经确定了各种机制，但对于 OC 细胞如何获得 PARPi 耐药性仍不完全了解。本研究使用高通量 RT-qPCR 和生物信息学分析，研究了奥拉帕利敏感（PEO1、PEO4）和先前建立的奥拉帕利耐药 OC 细胞系（PEO1-OR）中的 microRNA（miRNA）表达。使用 ATR/CHK1 通路抑制剂探索了 miRNA 在获得性耐药和再敏化中的作用。差异表达的 miRNA 用于构建 miRNA-mRNA 调控网络，并使用 miRNet 2.0 对靶基因进行功能富集分析。分析 TCGA-OV 数据集以探索选定 miRNA 和靶基因在临床样本中的预后价值。我们确定了与奥拉帕利耐药相关的潜在过程，包括细胞增殖、迁移、细胞周期和生长因子信号转导。再敏化的 PEO1-OR 细胞通过 PDGF、EGFR、FGFR1、VEGFR2 和 TGFβR 富集于生长因子信号转导，通过 G2/M 检查点调节细胞周期，通过 Caspase 介导的细胞凋亡。抗体微阵列分析证实了生长因子表达失调。ATR/CHK1 通路抑制剂与奥拉帕利联合使用可特异性地下调 PEO1-OR 细胞中的 FGF4、FGF6、NT-4、PLGF 和 TGFβ1。对浆液性 OC 患者的生存和差异表达分析显示，预后 miRNA 可能与奥拉帕利耐药（miR-99b-5p、miR-424-3p 和 miR-505-5p）和对奥拉帕利的再敏化（miR-324-5p 和 miR-424-3p）相关。基于预后 miRNA 和靶基因重建了关键的 miRNA-mRNA 相互作用。总之，我们的数据突出了奥拉帕利敏感和耐药细胞中独特的 miRNA 谱，为克服 OC 中 ATR/CHK1 抑制剂的耐药性提供了分子见解。此外，一些 miRNA 可能作为耐药性和治疗反应的潜在预测特征分子。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e5/11119970/5904a0435777/cells-13-00867-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e5/11119970/f1448daa017c/cells-13-00867-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e5/11119970/c63b939628bb/cells-13-00867-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e5/11119970/9317c8ff41c8/cells-13-00867-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e5/11119970/a7a91b71d657/cells-13-00867-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e5/11119970/5dab602ee859/cells-13-00867-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e5/11119970/b4754684300b/cells-13-00867-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e5/11119970/733f94a129c8/cells-13-00867-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e5/11119970/5904a0435777/cells-13-00867-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e5/11119970/f1448daa017c/cells-13-00867-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e5/11119970/c63b939628bb/cells-13-00867-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e5/11119970/9317c8ff41c8/cells-13-00867-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e5/11119970/a7a91b71d657/cells-13-00867-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e5/11119970/5dab602ee859/cells-13-00867-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e5/11119970/b4754684300b/cells-13-00867-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e5/11119970/733f94a129c8/cells-13-00867-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e5/11119970/5904a0435777/cells-13-00867-g008.jpg

相似文献

[1]
Uncovering miRNA-mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of Ovarian Cancer PEO1-OR Cells with the ATR/CHK1 Pathway Inhibitors.

Cells. 2024-5-17

[2]
Molecular mechanisms restoring olaparib efficacy through ATR/CHK1 pathway inhibition in olaparib-resistant BRCA1/2 ovarian cancer models.

Biochim Biophys Acta Mol Basis Dis. 2025-2

[3]
Olaparib-Resistant Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival.

Cells. 2023-3-29

[4]
Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2 ovarian cancer cells.

Sci Rep. 2023-12-19

[5]
PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.

Int J Mol Sci. 2020-12-19

[6]
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1.

J Exp Clin Cancer Res. 2020-1-2

[7]
LCP1 promotes ovarian cancer cell resistance to olaparib by activating the JAK2/STAT3 signalling pathway.

Cancer Biol Ther. 2024-12-31

[8]
Olaparib Combined with DDR Inhibitors Effectively Prevents EMT and Affects miRNA Regulation in -Mutated Epithelial Ovarian Cancer Cell Lines.

Int J Mol Sci. 2025-1-15

[9]
Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in -Mutant Ovarian Cancer Models.

Clin Cancer Res. 2017-6-15

[10]
The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous and Ovarian Cancer Cells.

Cells. 2022-6-10

引用本文的文献

[1]
Unraveling the Role of the microRNA-Mediated Regulation of Actin-Binding Proteins in Ovarian Cancer: A Narrative Review.

Cancers (Basel). 2025-7-11

[2]
Identification and analysis of microplastics in peritumoral and tumor tissues of colorectal cancer.

Sci Rep. 2025-5-8

[3]
The Role of microRNA in the Prognosis and Diagnosis of Ovarian Cancer.

Int J Mol Sci. 2025-4-5

[4]
Olaparib Combined with DDR Inhibitors Effectively Prevents EMT and Affects miRNA Regulation in -Mutated Epithelial Ovarian Cancer Cell Lines.

Int J Mol Sci. 2025-1-15

本文引用的文献

[1]
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.

Ann Oncol. 2024-3

[2]
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer.

Br J Cancer. 2024-4

[3]
Efficacy and safety of VEGF/VEGFR inhibitors for platinum-resistant ovarian cancer: a systematic review and meta-analysis of randomized controlled trials.

BMC Womens Health. 2024-1-13

[4]
Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2 ovarian cancer cells.

Sci Rep. 2023-12-19

[5]
Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib.

Cancers (Basel). 2023-8-1

[6]
Circulating microRNAs for Early Diagnosis of Ovarian Cancer: A Systematic Review and Meta-Analysis.

Biomolecules. 2023-5-22

[7]
Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer.

Clin Cancer Res. 2023-8-1

[8]
Olaparib-Resistant Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival.

Cells. 2023-3-29

[9]
Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer.

Ther Adv Med Oncol. 2023-3-1

[10]
Deregulated miRNA clusters in ovarian cancer: Imperative implications in personalized medicine.

Genes Dis. 2022-3-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索